NCT03258281View on ClinicalTrials.gov

Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus

PHASE4TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

September 1, 2019

Study Completion Date

October 1, 2019

Conditions
Diabetes Mellitus, Type 2Dyslipidemia Associated With Type II Diabetes MellitusPercutaneous Coronary Intervention
Interventions
DRUG

Evolocumab

Patients will receive evolocumab 420 mg administered subcutaneously

DRUG

Placebo

Patients will receive placebo administered subcutaneously

Trial Locations (1)

22042

Inova Fairfax Hospital, Falls Church

Sponsors
All Listed Sponsors
lead

Inova Health Care Services

OTHER